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Ischemia Detected on Continuous
Electrocardiography After Acute Coronary Syndrome
Observations From the MERLIN–TIMI 36 (Metabolic
Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation
Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction 36) Trial
Benjamin M. Scirica, MD, MPH,*† David A. Morrow, MD, MPH,*† Andrzej Budaj, MD, PHD,‡
Anthony J. Dalby, MD,§ Satishkumar Mohanavelu, MS,* Jie Qin, MS,* Julian Aroesty, MD,*
Chester M. Hedgepeth, MD, PHD,† Peter H. Stone, MD,† Eugene Braunwald, MD*†
Boston, Massachusetts; Warsaw, Poland; and Johannesburg, South Africa
Objectives The purpose of this study was to assess the relationship between ischemia detected on continuous electrocar-
diographic (cECG) recording and cardiovascular outcomes after acute coronary syndrome (ACS).
Background The small size of prior studies evaluating cECG prevented full evaluation of the risk associated with ischemia
across subpopulations and compared with other methods of risk stratification. Ranolazine, a new antianginal
agent, reduces ischemic symptoms in patients with chronic angina and after ACS but the anti-ischemic effect,
as detected by cECG, is not known.
Methods In all, 6,560 patients hospitalized with non–ST-segment elevation ACS were randomly assigned to ranolazine or
placebo in the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation
Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction 36) trial. The cECG was performed for 7 days
after randomization. Outcomes were followed for a median of 348 days. Clinical events that occurred during
cECG recording were excluded from analysis.
Results A total of 6,355 (97%) patients had cECG recordings evaluable for ischemia analysis. Patients with 1 episode
of ischemia on cECG (n  1,271, 20%) were at increased risk of cardiovascular death (7.7% vs. 2.7%, p 
0.001), MI (9.4% vs. 5.0%, p  0.001), and recurrent ischemia (17.5% vs. 12.3%, p  0.001). The relationship
with cardiovascular death was independent of baseline characteristics or elevated biomarkers (adjusted hazard
ratio: 2.46, p  0.001). Ischemia on cECG was associated with significantly worse outcomes in several subgroups.
Ranolazine did not reduce the rate of ischemia detected on cECG (19.9% vs. 21.0%, hazard ratio: 0.93, p  0.21).
Conclusions In more than 6,300 patients with ACS, ischemia detected on cECG occurred frequently and was strongly and
independently associated with poor cardiovascular outcomes, including cardiovascular death. Continuous ECG
monitoring to detect ischemia after ACS may help to identify patients at increased risk. (Metabolic Efficiency
With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes [MERLIN]; NCT00099788)
(J Am Coll Cardiol 2009;53:1411–21) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.053presentations from CV Therapeutics, and is supported in part by an unrestricted
research grant from Michael Lerner. Dr. Morrow receives honoraria for educational
presentations from CV Therapeutics and Sanofi-Aventis, serves as a consultant for
GlaxoSmithKline and Sanofi-Aventis, and is on the advisory board for Genentech.
Dr. Budaj receives honoraria from CV Therapeutics, AstraZeneca, GlaxoSmithKline,
Boehringer Ingelheim, and Sanofi-Aventis, and serves as a consultant to GlaxoSmith-
Kline and Sanofi-Aventis. Dr. Aroesty serves as a consultant to Fibrogen, which has
no commercial products and is conducting no research that could bear any relationship
to this paper. Dr. Stone receives a research grant from CV Therapeutics. Dr.
Braunwald receives honoraria from and serves as a consultant to AstraZeneca, Bayer
AG, CV Therapeutics, Daichii Sankyo, Merck, Pfizer, and Schering-Plough.ontinuing Medical Education (CME) is available for this article. Go to http://
me.jaccjournals.org to participate. From the *TIMI Study Group and †Cardiovas-
ular Division, Department of Medicine, Brigham and Women’s Hospital, and
arvard Medical School, Boston, Massachusetts; ‡Postgraduate Medical School,
rochowski Hospital, Warsaw, Poland; and the §Milpark Hospital, Johannesburg,
outh Africa. The MERLIN-TIMI 36 study was supported by CV Therapeutics.
he TIMI Study Group reports receiving significant research grant support from
ccumetrics, Amgen, AstraZeneca, Bayer Healthcare, Beckman Coulter, Biosite,
ristol-Myers Squibb, CV Therapeutics, Eli Lilly, GlaxoSmithKline, Inotek Phar-
aceuticals, Integrated Therapeutics, Merck & Co., Merck-Schering Plough Joint
enture, Millennium Pharmaceuticals, Novartis Pharmaceuticals, Nuvelo, Ortho-
linical Diagnostics, Pfizer, Roche Diagnostics, Sanofi-Aventis, Sanofi-Synthelabo,
nd Schering-Plough. Dr. Scirica receives honoraria for consulting and educational
Manuscript received October 15, 2008; revised manuscript received December 19,
2008, accepted December 22, 2008.
b
u
a
t
s
b
c
c
s
a
p
a
(
b
c
w
t
t
a
M
I
R
A
I
N
p
t
i
o
S
m
a
l
n
p
p
i
c
h
r
i
v
p
w
i
C
w
t
p
o
o
r
a
s
m
S
r
a
e
a
w
c
s
a
t
r
e
fi
b
c
s
m
4
p
L
p
(
(
t
t
(
d
v
S
p
w
1412 Scirica et al. JACC Vol. 53, No. 16, 2009
Ischemia Detected on Continuous ECG After ACS April 21, 2009:1411–21Despite advances in pharmacologi-
cal and interventional treatment of
patients with acute coronary syn-
drome (ACS), recurrent ischemia
may occur early after initial stabiliza-
tion and is generally considered to be
associated with poor cardiovascular
outcomes (1). Continuous electro-
cardiographic (cECG) monitoring
is a sensitive method to detect
and quantify recurrent myocar-
dial ischemia. Several prior stud-
ies found that ischemia as de-
tected on cECG monitoring was
associated with poor outcomes,
ut most such studies were performed before the widespread
se of an interventional strategy and potent adjunctive
ntiplatelet and antithrombotic therapy (2–9). Moreover,
he relatively small numbers of clinical events in these
tudies prevented a full examination of the association
etween cECG ischemia and clinical outcomes, particularly
ardiovascular death, across relevant subpopulations and in
omparison with other contemporary methods of risk
tratification.
See page 1422
Ranolazine, a piperazine derivative, is a novel antianginal
gent that reduces anginal frequency and improves exercise
erformance in patients with chronic stable angina (10–12)
nd reduces symptomatic recurrent ischemia after ACS
13). In this new analysis, we evaluated the association
etween ischemia as detected by cECG and clinical out-
omes in a large contemporary cohort of patients admitted
ith non–ST-segment elevation (NSTE) ACS and de-
ermined whether ranolazine would reduce ischemia de-
ected on cECG monitoring during the first week after
dmission.
ethods
n the MERLIN–TIMI 36 (Metabolic Efficiency with
anolazine for Less Ischemia in Non–ST-elevation
cute Coronary Syndrome–Thrombolysis In Myocardial
nfarction 36) trial, 6,560 patients hospitalized with
STE ACS were randomly assigned to ranolazine or
lacebo in addition to standard medical and invasive
herapy (14). Eligible patients had at least 10 min of
schemic symptoms at rest and presented with at least 1
f the following: elevated biomarkers of myonecrosis,
T-segment depression 0.1 mV, history of diabetes
ellitus, or an intermediate to high TIMI risk score (3)
nd received randomized assignment within 48 h of their
ast ischemic symptoms in a blinded manner to intrave-
ous ranolazine followed by oral ranolazine or matching
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BNP  B-type natriuretic
peptide
cECG  continuous
electrocardiography
HR  hazard ratio
IQR  interquartile range
MI  myocardial infarction
NSTE  non–ST-segment
elevationlacebo. Patients were stratified according to the treating ahysician’s intent to treat the patient with an early
nvasive versus conservative treatment strategy. Full in-
lusion and exclusion criteria, as well as study procedures,
ave been published previously (13,14). Exclusion criteria
elevant to this analysis include baseline ECG abnormal-
ties including left bundle branch block, predominant
entricular paced rhythm, significant left ventricular hy-
ertrophy, and concurrent digoxin use.
The primary end point of the MERLIN–TIMI 36 trial
as the composite of cardiovascular death and recurrent
schemic events. A cECG (Holter) recording (Lifecard
F, DelMar Reynolds/Spacelabs, Issaqua, Washington)
as to be performed for the first 7 days after randomiza-
ion in all patients to assess for ischemia as part of a
re-defined efficacy analysis (13,14). Analysts and cardi-
logists blinded to treatment assignment and clinical
utcomes performed ischemia analyses of all cECG
ecordings in the TIMI ECG Core Laboratory to detect
ny ischemic episode with 0.5 mm ST-segment depres-
ion lasting at least 1 min.
The primary ischemic end point of the cECG assess-
ent was the incidence of ischemia defined as 1 mm
T-segment depression lasting at least 1 min with a heart
ate at the onset of the episode 100 beats/min. Second-
ry cECG ischemic end points were pre-defined as
pisodes with 0.5 mm ST-segment depression lasting
t least 1 min, and the incidence of ischemia occurring
ithin 72 h of randomization. Ischemic burden was
alculated from the sum of the area under the ST-
egment trend curves for each ischemic episode (15).
All analyses comparing ischemia detected on cECG
nd clinical ischemic events excluded any component of
he primary end point (cardiovascular death, new or
ecurrent myocardial infarction [MI], or symptomatic
pisode of recurrent ischemia) that occurred within the
rst 7 days during the time of cECG monitoring. A
linded clinical events committee adjudicated cardiovas-
ular death, MI, and recurrent ischemia. The TIMI risk
core was calculated using the previously described
ethod and categorized as low (0 to 2), moderate (3 to
), or high (4) risk (16).
Blood samples were obtained at enrollment in 4,366
atients and analyzed in the TIMI Biomarker Core
aboratory (Boston, Massachusetts). B-type natriuretic
eptide (BNP) was measured using the ADVIA Centaur
Siemens Medical Solutions, Malvern, Pennsylvania)
17) using a pre-specified decision limit of 80 pg/ml on
he basis of our prior work (18). Levels of cardiac
roponin-I were measured using the TnI-ultra assay
Siemens Medical Solutions), which has a 99th percentile
ecision limit of 0.04 ng/ml with a 10% coefficient of
ariation.
tatistical analysis. All ischemia analyses were based on
atients with evaluable cECG data. Continuous data
ere compared with a t test for normally distributed datand a Wilcoxon rank sum test for non-normally distrib-
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April 21, 2009:1411–21 Ischemia Detected on Continuous ECG After ACSted data. Dichotomous variables were compared with a
hi-square test (14). Hazard ratios (HRs) and 95%
onfidence interval (CI) were estimated using a Cox
roportional hazards regression model. Clinical event
ates are presented as Kaplan-Meier failure rates that
ere calculated beginning at day 8 after randomization
hough 1 year. Receiver-operator characteristic curves
nd c-statistics were generated for the different multiva-
iable models that did and did not include ischemia
etected on cECG. Differences between models were
etermined by comparing likelihood ratio values for each
odel. All analyses reported in this manuscript were per-
ormed independently by the TIMI Study Group using
TATA/SE version 9.2 (STATA Corp., College Station,
exas) (13).
esults
f the 6,560 patients in the MERLIN–TIMI 36 trial,
,355 (97%) patients had cECG recordings that were
nterpretable for analysis. Continuous ECG monitoring
as not performed in 105 (1.7%) patients and technical
ailures in the recording of the cECG prevented analysis
f 100 (1.6%) recordings. The median duration of cECG
ecording was 6.0 days. A total of 39,340 patient-days
944,160 h) of cECG recordings was analyzed.
ncidence of ischemia on cECG. Overall, 1,271 (20%)
atients experienced at least 1 episode of ischemia on
ECG. Among the 1,271 patients who experienced at
east 1 episode of ischemia, the median number of
pisodes was 3 (interquartile range [IQR]: 1 to 7). A
Figure 1 Frequency of Ischemic Episodes Detected on cECG
Frequency of ischemic episodes by the day of continuous electrocardiographic (cEC
emic episodes per day. The blue bars represent the number of patients who exper
ber of patients who experienced their first episode of ischemia per day.istribution of the number of ischemic episodes per day,
he number of patients with an ischemic episode per day,
nd the number of patients with their first ischemic
pisode is presented in Figure 1. Two-thirds of patients
ad their first episode of ischemia within the first 48 h of
ECG monitoring. Among patients who experienced
schemia, the median total duration of ischemia was 119 min
IQR: 43 to 354 min), and the median ischemic burden was
4,987 mV/min (IQR: 15,532 to 1,283 mV·min).
linical correlates and incidence of ischemia detected on
ECG. Baseline characteristics of the 6,355 patients
ith valid cECGs are presented in Table 1 according to
hether they had ischemia on cECG or not. Patients
ith ischemia were more likely to be elderly, women,
ave impaired creatinine clearance or prior cardiovascular
isease including hypertension, angina, or heart failure,
nd on presentation, were more likely to have had
T-segment depression, an elevated BNP or troponin, or
igh TIMI risk score. There was no difference in the rate
f ischemia according to an invasive versus conservative
trategy within the first 72 h after randomization (15.2%
s. 16.3%, p  0.25), but there was a significantly lower
ate of ischemia after 72 h (2.8% vs. 5.0%, p  0.001)
mong patients for whom the treating physician selected
n early invasive strategy.
Revascularization during the index procedure was more
requent among patients who had episodes of ischemia
etected on cECG. There was similar if not higher use of
ntianginal therapy (beta-blockers, nitrates, or calcium
ntagonist) but less use of thienopyridines or statins in
cording after randomization. The yellow bars represent the total number of isch-
at least 1 episode of ischemia per day, and the green bars represent the num-G) re
ienced
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Ischemia Detected on Continuous ECG After ACS April 21, 2009:1411–21atients with an episode of ischemia detected on cECG
ompared with patients who had no episodes of ischemia
etected.
schemia detected on cECG and clinical outcomes. Pa-
ients with at least 1 episode of ischemia were at
ncreased risk of each component of the primary end
oint, including cardiovascular death (Table 2). Patients
Baseline Characteristics in Patients With cECG
Table 1 Baseline Characteristics in Patients
Characteristics
Age, yrs, mean (SD)
Age 65 yrs, %
Female, %
Body mass index, kg/m2, median (Q1, Q3)
Comorbidities, %
Diabetes mellitus
Hypertension
Current smoker, %
Cardiac history, %
Prior MI
Prior revascularization
Prior angina
Prior heart failure
Creatinine clearance 60 ml/min, %
Index event, %
Unstable angina
Non–ST-segment elevation MI
ST-segment depression 0.1 mV on admission, %
Elevated troponin (0.04 mg/l), %
Elevated BNP (80 pg/ml), %
TIMI risk score, %
0–2
3–4
5–7
Intent of early invasive strategy, %
Intent of conservative strategy, %
Revascularization during index hospitalization, %
Cardiac medications during index hospitalization, %
Aspirin
Heparin
Thienopyridine
Beta-blockers
ACE inhibitors or ARBs
Statins
Nitrates
Calcium antagonist
Cardiac medications at discharge, %
Aspirin
Thienopyridine
Beta-blockers
ACE inhibitors or ARBs
Statins
Nitrates
Calcium antagonist
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor b
graphic; MI  myocardial infarction; Q  quartile; TIMI  Thrombolysith 2 episodes of ischemia were at even greater risk aompared with patients who had only 1 or 2 episodes
Fig. 2).
Table 3 presents both the incidence of ischemia within
ultiple subgroups and the associated risk of cardiovas-
ular death and the primary end point. Patients with the
ighest incidence of cardiovascular death (10%) in-
luded those with both high-risk clinical features (e.g.,
itoring
h cECG Monitoring
emia on cECG
 1,271)
No Ischemia
(n  5,084) p Value
(10.3) 62.7 (11.0) 0.001
60.8 46.1 0.001
38.6 34.2 0.003
(24.8, 30.5) 28.4 (25.6, 31.6) 0.001
32.1 34.3 0.13
77.1 72.9 0.002
19.8 26.8 0.001
33.9 34.3 0.79
24.2 27.2 0.032
66.4 53.0 0.001
20.7 15.9 0.001
29.8 19.4 0.001
46.2 48.3 0.19
53.8 51.7
61.1 28.9 0.001
71.6 63.0 0.001
53.2 39.7 0.001
17.5 29.2 0.001
50.0 53.3
32.6 17.6
36.4 41.4 0.001
63.6 58.6 0.001
42.3 38.6 0.015
87.3 88.3 0.31
90.6 90.3 0.73
58.1 61.6 0.02
83.3 83.5 0.91
73.5 69.5 0.005
70.8 74.9 0.003
88.0 83.5 0.001
33.6 29.3 0.003
86.5 86.8 0.73
48.5 53.7 0.001
75.9 78.1 0.095
71.1 71.3 0.91
74.2 78.0 0.004
38.6 28.3 0.001
28.7 35.4 0.015
BNP  B-type natriuretic peptide; cECG  continuous electrocardio-
ocardial Infarction.Mon
Wit
Isch
(n
66.6
27.6ge 65 years, prior heart failure) in addition to ischemia
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April 21, 2009:1411–21 Ischemia Detected on Continuous ECG After ACSetected on cECG. Conversely, the absence of ischemia
n any of the following low-risk populations—low BNP,
ndetectable level of troponin, age 65 years, or low
IMI risk score—identified a cohort with a particularly
ow rate of cardiovascular death (2.5%). Even among
atients with a relatively low absolute risk of cardiovas-
ular death, the relative risk associated with ischemia on
ECG was particularly high. For example, the HR for
ardiovascular death was 3.8 for patients with normal
jection fraction but with ischemia on cECG (p for
nteraction  0.012 compared with no ischemia) and 4.7
or patients with a BNP 80 pg/ml and ischemia
etected on cECG (p for interaction  0.049). In a very
ow clinical risk population (i.e., no ECG changes on
dmission, negative troponin, and BNP 80 pg/ml, n 
5), ischemia on cECG was still strongly associated with
n increased risk of cardiovascular death (5.1% vs. 0.6%;
R: 5.2, 95% CI: 1.52 to 17.79, p  0.008).
In a multivariable model that included clinical charac-
eristics and biomarker data, ischemia detected on cECG
ontinued to be strongly and independently associated
ith all clinical ischemic end points, including cardiovas-
ular death (Table 4) The addition of ischemia on cECG
o the multivariable model significantly increased the
-statistic from the receiver-operating curves for both
ardiovascular death (0.81 vs. 0.79, p  0.001) and the
rimary end point (0.62 vs. 0.61, p  0.001).
This relationship between ischemia and outcomes was
onsistent among patients who underwent a conservative
anagement strategy (HR with ischemia: 3.0, 95% CI: 2.3 to
.1, p 0.001 for cardiovascular death, and HR: 1.8, 95% CI:
.5 to 2.1, p  0.001 for the primary end point) or an early
nvasive strategy (HR with ischemia: 2.2, 95% CI: 1.2 to 3.9,
 0.008 for cardiovascular death, and HR: 1.6, 95% CI: 1.3
o 2.0, p  0.001 for the primary end point).
arly versus late ischemia. The association between
schemia on cECG and clinical outcomes was also similar
f the first ischemic event occurred within the first 48 h
fter randomization (rate of cardiovascular death of 8.0%
or patients with ischemia vs. 3.0% for patients with no
schemia, HR: 2.50, 95% CI: 1.88 to 3.32, p  0.001;
ncidence of Ischemia on cECG and Association With Clinical End P
Table 2 Incidence of Ischemia on cECG and Association With C
Ischemia on cECG
(n  1,271) (%)
Primary end point: cardiovascular death/
MI/recurrent ischemia
28.5
Major secondary end point: cardiovascular death/
MI/severe recurrent ischemia
23.7
Cardiovascular death/MI 14.9
Cardiovascular death 7.7
MI 9.4
Recurrent ischemia 17.5
I  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.nd for the primary end point, 27.8% vs. 18.7%, HR: l.60, 95% CI: 1.38 to 1.86, p  0.001), or if the first
schemic episode occurred 48 h after randomization
rate of cardiovascular death 7.2% with ischemia vs. 3.5%
ithout ischemia, HR: 2.42, 95% CI: 1.68 to 3.48, p 
.001; and for the primary end point, 29.8% vs. 19.2%,
R: 1.71, 95% CI: 1.41 to 2.07, p  0.001).
schemia before and after revascularization. A total of
,494 (39.3%) patients underwent coronary revasculariza-
ion during their index hospitalization. Of these, patients
ho experienced at least 1 episode of ischemia on cECG
efore revascularization (n  422), were at increased risk
f cardiovascular death (3.2% vs. 1.7%, HR: 2.3, 95% CI:
.3 to 4.2, p  0.004) or the primary end point (23.1% vs.
8.0%, HR: 1.4, 95% CI: 1.1 to 1.8, p  0.004). Fewer
atients had an ischemic episode on cECG after revas-
ularization (n  109), but the presence of ischemia on
ECG was also associated with an increased risk of the
rimary end point (30.7% vs. 18.3%, HR: 1.8, 95% CI:
.2 to 2.7, p  0.002) and numerical, although nonsig-
ificant, increase in the risk of cardiovascular death (3.8%
s. 1.9%, HR: 1.7, 95% CI: 0.62 to 4.8, p  0.30).
schemia according to extent of coronary artery disease.
mong patients who underwent angiography (n 
,789), there was a stepwise increase in the incidence of
schemia on cECG with a greater extent of coronary
rtery disease (defined as a lesion 50% stenosis) ranging
rom 10.4% for patients with no significant epicardial
isease (n  442), 12.3% for patients with 1-vessel
isease (n  1,063), 18.9% for 2-vessel disease (n  954),
nd 28.0% for 3-vessel disease (n  1,330). Even among
atients with minimal epicardial disease (0- or 1-vessel
isease), ischemia on cECG was associated with in-
reased risk cardiovascular death (4.4% vs. 0.5%, HR: 6.1,
5% CI: 2.4 to 15.5, p  0.001).
Among patients who after revascularization had no
esidual lesions 50% stenosis (n  1361), the presence
f at least 1 episode of ischemia on cECG was associated
ith a significantly greater risk of cardiovascular death
3.4% vs. 1.0%, HR: 3.3, 95% CI: 1.4 to 7.9, p  0.006).
T-segment elevation. A total of 204 (3.2%) patients expe-
ienced at least 1 episode of ST-segment elevation 1 mm
s
al End Points
No Ischemia on cECG
(n  5,084) (%) Unadjusted HR (95% CI) p Value
17.8 1.75 (1.54–1.99) 0.001
14.1 1.84 (1.60–2.12) 0.001
6.8 2.31 (1.93–2.76) 0.001
2.7 2.94 (2.27–3.81) 0.001
5.0 2.00 (1.60–2.51) 0.001
12.3 1.43 (1.2–1.69) 0.001oint
linicasting 1 min, although many (40%) of these patients also
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Ischemia Detected on Continuous ECG After ACS April 21, 2009:1411–21xperienced ST-segment depression. Compared with patients
ith no ST-segment deviation, patients with ST-segment
levation were not at greater risk of cardiovascular death (3.2%
s. 2.7%, HR: 1.3, 95% CI: 0.61 to 2.8, p  0.51) and only
lightly greater risk of the primary end point (25.7% vs. 17.9%,
R: 1.4, 95% CI: 1.03 to 2.0, p  0.03).
schemic episodes of only 0.5 to 1.0 mm depression. A
otal of 246 (3.9%) patients experienced only ischemic
pisodes limited to 0.5 to 1.0 mm of ST-segment
epression. That degree of ST-segment depression alone
Figure 2 Ischemia Detected on cECG and Cardiac Outcomes
Cumulative incidence of cardiovascular death (A) and the primary end point of car
the number of ischemic episodes detected on continuous electrocardiography (cEC
the green lines represent no episodes. HR  hazard ratio.as not associated with an increased risk of subsequent 0ardiovascular events compared with patients without any
schemia (2.9% vs. 2.6%, HR: 0.88, 95% CI: 0.39 to 2.00,
 0.76 for cardiovascular death alone; and 17.1% vs.
7.7%, HR: 0.92, 95% CI: 0.66 to 1.26, p  0.59 for the
rimary end point).
ffect of ranolazine on cECG ischemia. Treatment with
anolazine did not reduce the incidence of the primary
ECG ischemic end point of 1 mm of ST-segment
epression lasting 1 min with a heart rate 100 beats/
in (19.9% for ranolazine vs. 21.0% for placebo, HR:
cular death, myocardial infarction (MI), or recurrent ischemia (B) according to
e red lines represent 2 episodes; the blue lines represent 1 to 2 episodes;diovas
G). Th.93, 95% CI: 0.84 to 1.04, p  0.21). However,
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April 21, 2009:1411–21 Ischemia Detected on Continuous ECG After ACSanolazine did result in a greater reduction in the inci-
ence of a pre-specified secondary ischemic definition of
T-segment depression of 0.5 mm (23.5% vs. 26.2%,
R: 0.89, 95% CI: 0.81 to 0.98, p  0.02) and, in an
xploratory analyses, was numerically more pronounced
ncidence of Ischemia on cECG in Various Populations and Associa
Table 3 Incidence of Ischemia on cECG in Various Populations
C
Characteristics
Ischemia on
cECG (%) p Value Ischemia
N
Isch
Male (n  4,128) 18.9 0.003 7.9
Female (n  2,227) 22.1 7.5
65 yrs of age (n  3,239) 15.4 0.001 3.2
65 yrs of age (n  3,116) 24.8 10.9
No prior HTN (n  4,653) 17.4 0.002 5.3
Prior HTN (n  1,659) 20.9 8.6
No DM (n  4,202) 20.5 0.134 7.1
DM (n  2,153) 19.0 9.2
No prior angina (n  3,475) 15.3 0.001 5.2
Prior angina (n  2,768) 23.9 8.9
No prior MI (n  4,142) 20.1 0.79 5.7
Prior MI (n  2,151) 19.9 11.4
No prior revascularization (n  4,661) 20.7 0.032 8.4
Prior revascularization (n  1,690) 18.2 5.9
No prior HF (n  5,286) 19.1 0.001 4.7
Prior HF (n  1,069) 24.6 18.9
Unstable angina (n  2,874) 19.5 0.19 7.4
NSTEMI (n  3,240) 20.9 8.2
No STSD 1 mm on admission
(n  4,109)
12.1 0.001 3.8
STSD 1 mm on admission
(n  2,246)
34.6 10.3
Low TRS: 0–2 (n  1,704) 13.0 0.001 0.9
Moderate TRS: 3–4 (n  3,343) 19.0 6.9
High TRS: 5–7 (n  1,308) 31.7 13.1
Conservative strategy (n  3,116) 21.3 0.001 10.4
Early invasive strategy (n  3,116) 18.0 3.0
EF 40% (n  3,116) 20.0 0.79 7.4
EF 40% (n  3,116) 19.5 13.0 1
Negative cTnI (n  1,550) 16.5 0.001 5.5
Positive cTnI (n  2843) 22.7 10.5
Normal BNP, 80 pg/ml (n  2,542) 16.7 0.001 5.4
Elevated BNP, 80 pg/ml (n  1,876) 25.6 12.1
TnI  cardiac troponin-I; DM  diabetes mellitus; EF  ejection fraction; HF  heart failure; H
epression; TRS  Thrombolysis In Myocardial Infarction risk score; other abbreviations as in Tab
Adjusted Risk of Cardiovascular ComplicationsWith Clinical, Biochemic l, and Electro rdiogra
Table 4 Adjusted Risk of Cardiovascular CoWith Clinical, Biochemical, and Ele
Cardi
Characteristics Adjusted HR
Ischemia on cECG 2.46 (1.8
Moderate TIMI risk score 2.52 (1.3
High TIMI risk score 3.58 (1.9
Creatinine clearance 60 ml/min 2.07 (1.5
Elevated cardiac troponin-I, 0.04 mg/ml 1.97 (1.3
Elevated BNP, 80 pg/ml 2.34 (1.6
Revascularization during index event 0.28 (0.1Abbreviations as in Tables 1 and 2.hen examining events that occurred 72 h after ran-
omization (Fig. 3A) and among episodes that had a
igher heart rate at the onset of the event (Fig. 3B).
here was no difference in the effect of ranolazine on
linical outcomes among patients who did or did not
With Clinical Outcomes
Association With Clinical Outcomes
ascular Death Primary End Point
HR (95% CI)
p Value for
Interaction Ischemia
No
Ischemia HR (95% CI)
p Value for
Interaction
3.7 (2.7–5.2) 0.023 27.5 17.5 1.7 (1.5–2.1) 0.99
2.0 (1.3–3.0) 29.9 18.5 1.7 (1.4–2.1)
2.3 (1.3–4.0) 0.65 21.2 16.1 1.4 (1.1–1.7) 0.026
2.7 (2.0–3.6) 33.5 20.0 1.9 (1.6–2.2)
2.8 (1.5–5.1) 0.87 21.2 14.2 1.5 (1.1–2.0) 0.27
3.0 (2.2–3.9) 30.6 19.2 1.8 (1.6–2.1)
3.6 (2.6–5.0) 0.098 25.9 15.9 1.8 (1.5–2.1) 0.97
2.3 (1.5–3.5) 34.0 21.5 1.8 (1.4–2.2)
2.7 (1.6–4.4) 0.89 21.7 12.8 1.7 (1.3–2.2) 0.77
2.8 (2.0–3.8) 31.8 22.0 1.6 (1.4–1.9)
2.7 (1.9–3.9) 0.54 25.9 14.8 1.9 (1.6–2.2) 0.20
3.2 (2.2–4.7) 33.4 23.6 1.6 (1.3–2.0)
3.1 (2.3–4.2) 0.30 26.2 15.7 1.9 (1.6–2.2) 0.39
2.3 (1.3–4.0) 35.8 23.6 1.7 (1.3–2.1)
2.7 (1.9–3.8) 0.96 26.0 16.4 1.7 (1.5–2.0) 0.85
2.8 (1.9–4.1) 37.4 25.6 1.7 (1.3–2.1)
3.8 (2.5–5.8) 0.11 28.1 18.3 1.6 (1.4–2.0) 0.36
2.5 (1.8–3.5) 28.8 17.6 1.8 (1.5–2.2)
2.2 (1.3–3.6) 0.92 23.0 17.6 1.3 (1.1–1.7) 0.006
2.1 (1.5–2.9) 32.0 18.5 1.9 (1.6–2.3)
1.0 (.29–3.3) 15.0 11.9 1.2 (0.9–1.8)
2.7 (1.9–3.9) 0.12 27.2 18.6 1.6 (1.3–1.9) 0.26
2.6 (1.7–3.8) 0.14 38.7 25.7 1.8 (1.4–2.2) 0.097
3.0 (2.3–4.1) 0.31 30.9 19.2 1.8 (1.5–2.1) 0.47
2.2 (1.2–3.9) 24.0 15.9 1.6 (1.3–2.0)
3.8 (2.7–5.5) 0.012 27.1 15.7 1.9 (1.6–2.2) 0.73
1.4 (0.7–2.8) 40.0 24.8 2.1 (1.3–3.2)
4.3 (2.1–8.8) 0.38 22.9 15.7 1.5 (1.1–2.0) 0.13
3.0 (2.2–4.2) 31.1 18.6 1.9 (1.6–2.3)
4.7 (2.6–8.6) 0.049 23.7 16.1 1.6 (1.2–2.0) 0.30
2.3 (1.7–3.3) 32.8 20.0 1.8 (1.5–2.2)
hypertension; NSTEMI  non–ST-segment elevation myocardial infarction; STSD  ST-segment
d 2.
iatedFeatures
ations Associated
ardiographic Features
ular Death Primary End Point
CI) p Value Adjusted HR (95% CI) p Value
) 0.001 1.57 (1.34–1.83) 0.001
) 0.003 1.53 (1.26–1.87) 0.001
) 0.001 2.1 (1.70–2.65) 0.001
) 0.001 1.28 (1.08–1.50) 0.004
) 0.001 1.22 (1.04–1.44) 0.018
) 0.001 1.13 (0.97–1.31) 0.125
) 0.001 0.88 (0.76–1.03) 0.103tion
and
ardiov
o
emia
2.3
3.6
1.3
4.3
2.1
2.9
2.1
3.9
2.0
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3.7
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2.9
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1.9
3.4
1.8
5.0
1.0
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5.4
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1.0
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Ischemia Detected on Continuous ECG After ACS April 21, 2009:1411–21xperience ischemia on cECG (incidence of cardiovascu-
ar death 7.5% vs. 8.0%, HR: 1.08, 95% CI: 0.73 to 1.6,
 0.71 for patients with ischemia, and 2.6% vs. 2.8%,
R: 0.83, 95% CI: 0.60 to 1.2, p  0.28 for patients with
o ischemia, p for interaction  0.33; 26.5% vs. 30.3%,
R: 0.88, 95% CI: 0.71 to 1.1, p  0.26 in patients with
schemia, and for the primary end point, 17.2% vs. 18.5%, HR:
.92, 95% CI: 0.80 to 1.05, p  0.22 for patients with no
schemia, p for interaction  0.74).
iscussion
ith more than 6,300 patients and almost 40,000
 

Figure 3 Effect of Ranolazine on Ischemia Detected on cECG
(A) The effect of ranolazine on ischemic episodes that occurred 72 h after random
There was no statistical interaction between timing of the event and treatment wit
to the heart rate at the onset of ST-segment depression. cECG  continuous elecatient-days of recordings, this is the largest reported cECG or Holter assessment of patients with coronary
rtery disease. In this contemporary cohort of patients
ith NSTE ACS, recurrent ischemia as detected on
ECG during the first week after hospitalization occurred
requently and was strongly associated with a higher risk
f recurrent clinical events, including cardiovascular
eath beyond the first week. The poor prognosis associ-
ted with recurrent ischemia was observed in a population
eceiving contemporary interventional and pharmacologic
herapy. Data regarding ischemic on cECG significantly
mproved the ability to identify patients at greatest risk in
onjunction with standard risk stratification tools (e.g.,
n. Patients who had events during the first 72 h were included in this analysis.
lazine. (B) The relationship between ischemic episodes and ranolazine according
iographic monitoring; HR  hazard ratio.izatio
h rano
trocardlinical risk scores and biomarkers).
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April 21, 2009:1411–21 Ischemia Detected on Continuous ECG After ACSECG for risk assessment after ACS. In other studies of
ECG from the past 2 decades, ischemia on cECG has been
eported in 8% to 46% of patients admitted with ACS,
epending on the clinical scenario and the duration of
ECG recording (7). Several of the more recent and largest
tudies to date report an incidence of ischemia at 48 h
etween 15% and 25% (2,6,19). In the MERLIN–TIMI 36
rial, the rate of ischemia on cECG at 7 days was 20%, but
15% by 48 h, likely reflecting the more aggressive medical
nd interventional therapy given to patients in this study
uring the index hospitalization (13). Despite the high rate
f utilization of guideline-recommended therapies, recur-
ent ischemia detected on cECG still occurred fre-
uently, and when it did, carried a very poor prognosis,
ven among patients who would otherwise be considered
ow risk or among patients who had successful
evascularization.
Prior studies of cECG in ACS have demonstrated an
ssociation between ischemia on cECG and clinical out-
omes but have not had sufficient power to reliably examine
ardiovascular mortality alone. In a meta-analysis that
ncluded 995 patients and 8,923 h of recording, recurrent
schemia on cECG was associated with the composite of
eath or MI (2). Another study of 681 patients with NSTE
CS found that ST-segment deviation discovered on 48-h
ECG monitoring was associated with an increased risk of
eath and MI over the first 30 days after admission (6). Few
tudies, though, have demonstrated an independent rela-
ionship between ischemia on cECG and cardiovascular
eath alone, as observed in the MERLIN–TIMI 36 trial. In
ddition, prior studies of cECG were at most 48 h in
uration and therefore captured only a short period of
linical events. The improvements in technology that permit
days of cECG monitoring demonstrate that late ischemic
pisodes continue to occur many days after admission and
re associated with worse outcomes.
The large observation time during cECG monitoring
n this study permitted us a more detailed evaluation of
he clinical correlates of recurrent cECG ischemia than
reviously performed, a more thorough adjustment for
ther clinical risk indicators, and evaluation in conjunc-
ion with other tools for risk stratification. We found that
he relationship between ischemia on cECG and clinical
utcomes, including cardiovascular death, remained in-
ependent and consistent in important subgroups of
linical interest, and after comprehensive multivariable
djustment. Notably, ischemia on cECG significantly
mproved the prognostic discriminatory capacity (c-
tatistic) of clinical characteristics and biomarker data. This
mprovement contrasts with that from other tools for risk
tratification, such as novel biomarkers (20) Furthermore,
here were some populations in which the absence or
resence of ischemia on cECG identified an especially low-
r high-risk group. For example, patients with a normal
evel of BNP and no ischemia on cECG had a low (1.0%)
ncidence of cardiovascular death whereas the rate was 5.4% tor patients with low BNP and evidence of ischemia on
ECG. Moreover, there was a10-fold higher incidence of
ardiovascular death (12.1%) among patients who had both
n elevated BNP and ischemia detected on cECG compared
ith patients who had normal BNP and no ischemia. A
imilar divergent and increased risk of cardiovascular death
ccording to the presence of ischemia was also observed
mong patients65 years old, with a history of MI or heart
ailure, or with an elevated troponin level or high TIMI risk
core.
anolazine and cECG ischemia. Ranolazine has been
hown to reduce anginal frequency without clinically
ignificant effects on the heart rate or blood pressure
10 –12). In our study, ranolazine had a modest, nonsig-
ificant effect on ischemia detected on cECG during the
rst 7 days after admission ACS. The effect was slightly
reater using a broader definition of ischemia and when
xamining events that occurred several days after admis-
ion or events that were selected to be potentially demand
elated, occurring with a faster heart rate at onset.
Nevertheless, our findings indicate that during the
cute phase of ACS, ranolazine does not exert a clinically
elevant anti-ischemic effect as detected by cECG. These
ndings are consistent with the overall MERLIN–TIMI
6 trial in which there was a similar 8% reduction in
ymptomatic ischemia during the first 30 days after
andomization among patients assigned to ranolazine.
he lack of significant reduction in ischemia detected on
ECG is in contrast, though, to both the long-term
ERLIN–TIMI 36 findings with respect to recurrent
ymptomatic ischemia, where treatment with ranolazine
esulted in 13% significant reduction in symptomatic
ecurrent ischemia (13), and in studies of patients with
table angina where treatment with ranolazine not only
educed angina but also prolonged time to ST-segment
epression during exercise stress tests (10 –12).
The divergent results from these 2 different clinical
ettings—the early phase of ACS versus chronic ischemic
eart disease—may relate to the different predominant
nderlying etiologies of ischemia in these situations. During
he initial presentation with ACS and plausibly during early
ecurrence, ischemia is principally driven by reduced myo-
ardial oxygen supply due to stuttering atherothrombotic
bstruction of epicardial coronary arterial flow; whereas
fter the successful treatment of ACS (and in the case of
hronic angina) when the acute thrombus has dissipated,
schemia is more frequently due to increased oxygen de-
and exceeding the supply through fixed epicardial or
mall-vessel disease. Commensurate with this hypothesis,
rior studies in which a reduction of ischemia on cECG was
chieved used potent antiplatelet and antithrombin agents
4,8,19,21). Ranolazine, which is believed to predominately
mprove the “demand side” of ischemia would thus be more
ikely to benefit the treatment of chronic angina but less
ikely to modify the sudden ischemia from a rapidly growing
hrombus. Even if ranolazine improves coronary perfusion
b
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Ischemia Detected on Continuous ECG After ACS April 21, 2009:1411–21y reducing left ventricular end-diastolic pressures, as sug-
ested in animal models (22), it may not be able to
ompensate sufficiently to counteract an occlusive thrombus.
tudy limitations. We were unable to assess how many of
he ischemic event captured on cECG were associated with
linical symptoms and thus cannot determine what propor-
ion of ischemia was “asymptomatic” versus episodes also
anifested by symptoms. However, to ensure that the
elationship between ischemia on cECG and clinical out-
omes was a true association and not simply due to
double-counting” of an ischemic event detected on cECG
hat also resulted in a component of the primary end point,
e specifically excluded from our analysis any event that
ccurred during the period of cECG monitoring. If any-
hing, this approach would weaken the association between
schemia on cECG and outcomes because we likely ex-
luded some clinical events that occurred hours or days after
he episode of cECG but still within the first 7 days of
dmission. In addition, the MERLIN–TIMI 36 trial ex-
luded patients with significant baseline ECG abnormali-
ies, and therefore these findings cannot be extended to all
atients, such as those with significant repolarization abnor-
alities on the resting ECG. Given the neutral primary
fficacy analysis of the main trial, the analyses of ranolazine
nd cECG ischemia must be regarded as exploratory in
ature. The analyses of cECG ischemia by heart rate at
nset were post-hoc for the purpose of exploring the
echanistic hypotheses articulated in the discussion.
For this clinical protocol, we modified standard cECG
onitoring software to extend the recording time up to 7
ays. While that is longer than the typical 24- or 48-h
eriod used in clinical practice, we demonstrate that ex-
ended monitoring identifies many ischemic episodes that
ccur after 48 h and would therefore be missed with
tandard cECG recordings.
onclusions
n accordance with current practice guidelines (23,24),
ECG monitoring should be routinely performed for all
atients admitted with ACS. In practice, though, clinical
mphasis centers on the detection of arrhythmias, and
egardless of the recommendations of some (25), less effort
s focused on monitoring ST-segment deviation despite
echnologic advances that make such review easier to per-
orm. Our data suggest that despite contemporary therapy
ith potent antiplatelet and antithrombotic therapy, includ-
ng glycoprotein IIb/IIIa inhibitors and thienopyridines,
nd widespread use of revascularization, recurrent ischemia
s detected on cECG remains frequent, and when it occurs,
arries a poor prognosis. The detection of ischemia by
ECG therefore provides incremental prognostic informa-
ion with which to assess the risk of recurrent major
ardiovascular events in patients after NSTE ACS.eprint requests and correspondence: Dr. Benjamin M. Scirica,
IMI Study Group, Cardiovascular Division, Brigham and Women’s
ospital, 75 Francis Street, Boston, Massachusetts 02115. E-mail:
scirica@partners.org.
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